The Role of CircRNAs in Regulation of Drug Resistance in Ovarian Cancer

Overview

Journal Front Genet

Date 2023 Dec 28

PMID 38152652

Authors

Jun Zhan

Zhiyi Li

Changsheng Lin

Dingding Wang

Lei Yu

Xue Xiao

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the female reproductive system tumors. Chemotherapy is used for advanced ovarian cancer patients; however, drug resistance is a pivotal cause of chemotherapeutic failure. Hence, it is critical to explore the molecular mechanisms of drug resistance of ovarian cancer cells and to ameliorate chemoresistance. Noncoding RNAs (ncRNAs) have been identified to critically participate in drug sensitivity in a variety of human cancers, including ovarian cancer. Among ncRNAs, circRNAs sponge miRNAs and prevent miRNAs from regulation of their target mRNAs. CircRNAs can interact with DNA or proteins to modulate gene expression. In this review, we briefly describe the biological functions of circRNAs in the development and progression of ovarian cancer. Moreover, we discuss the underneath regulatory molecular mechanisms of circRNAs on governing drug resistance in ovarian cancer. Furthermore, we mention the novel strategies to overcome drug resistance via targeting circRNAs in ovarian cancer. Due to that circRNAs play a key role in modulation of drug resistance in ovarian cancer, targeting circRNAs could be a novel approach for attenuation of chemoresistance in ovarian cancer.

References

Wang J, Li H . CircRNA circ_0067934 silencing inhibits the proliferation, migration and invasion of NSCLC cells and correlates with unfavorable prognosis in NSCLC. Eur Rev Med Pharmacol Sci. 2018; 22(10):3053-3060. DOI: 10.26355/eurrev_201805_15063. View

Jin Y, Wang H . Circ_0078607 inhibits the progression of ovarian cancer via regulating the miR-32-5p/SIK1 network. J Ovarian Res. 2022; 15(1):3. PMC: 8729016. DOI: 10.1186/s13048-021-00931-9. View

An J, Lv W, Zhang Y . LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017; 10:5377-5390. PMC: 5691924. DOI: 10.2147/OTT.S147586. View

Wang W, Liu W, Chen Q, Yuan Y, Wang P . Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy. Semin Cancer Biol. 2022; 87:84-97. DOI: 10.1016/j.semcancer.2022.11.002. View

Freedy A, Liau B . Discovering new biology with drug-resistance alleles. Nat Chem Biol. 2021; 17(12):1219-1229. PMC: 9530778. DOI: 10.1038/s41589-021-00865-9. View

An Q, Liu T, Wang M, Yang Y, Zhang Z, Lin Z . circKRT7-miR-29a-3p-COL1A1 Axis Promotes Ovarian Cancer Cell Progression. Onco Targets Ther. 2020; 13:8963-8976. PMC: 7490051. DOI: 10.2147/OTT.S259033. View

Cai W, Zhang Q . The transcription factor ZEB1 mediates the progression of epithelial ovarian cancer by promoting the transcription of CircANKRD17. J Biochem Mol Toxicol. 2022; 36(8):e23086. DOI: 10.1002/jbt.23086. View

You J, Han Y, Qiao H, Han Y, Lu X, Lu Y . Hsa_circ_0063804 enhances ovarian cancer cells proliferation and resistance to cisplatin by targeting miR-1276/CLU axis. Aging (Albany NY). 2022; 14(11):4699-4713. PMC: 9217714. DOI: 10.18632/aging.203474. View

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

10.

Qiu Y, Chen Y, Agbede O, Eshaghi E, Peng C . Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets. Cancers (Basel). 2022; 14(22). PMC: 9688053. DOI: 10.3390/cancers14225711. View

11.

Liu Y, Jiang Y, Xu L, Qu C, Zhang L, Xiao X . circ-NRIP1 Promotes Glycolysis and Tumor Progression by Regulating miR-186-5p/MYH9 Axis in Gastric Cancer. Cancer Manag Res. 2020; 12:5945-5956. PMC: 7381786. DOI: 10.2147/CMAR.S245941. View

12.

Zhang H, Ma X, Li X, Deng F . Circular RNA circ_0067934 exhaustion expedites cell apoptosis and represses cell proliferation, migration and invasion in thyroid cancer via sponging miR-1304 and regulating CXCR1 expression. Eur Rev Med Pharmacol Sci. 2019; 23(24):10851-10866. DOI: 10.26355/eurrev_201912_19789. View

13.

Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W . Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression. Hum Cell. 2022; 35(5):1560-1576. DOI: 10.1007/s13577-022-00748-8. View

14.

Zhang X, Liu Q, Zhang J, Song C, Han Z, Wang J . The emerging role of lncRNAs in osteoarthritis development and potential therapy. Front Genet. 2023; 14:1273933. PMC: 10538550. DOI: 10.3389/fgene.2023.1273933. View

15.

Zou J, Liu L, Wang Q, Yin F, Yang Z, Zhang W . Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res. 2017; 9(3):1357-1368. PMC: 5376026. View

16.

Wang H, Yan X, Zhang H, Zhan X . CircRNA circ_0067934 Overexpression Correlates with Poor Prognosis and Promotes Thyroid Carcinoma Progression. Med Sci Monit. 2019; 25:1342-1349. PMC: 6390454. DOI: 10.12659/MSM.913463. View

17.

Wu H, Zhao X, Wang J, Jiang X, Cheng Y, He Y . Circular RNA CDR1as Alleviates Cisplatin-Based Chemoresistance by Suppressing MiR-1299 in Ovarian Cancer. Front Genet. 2022; 12:815448. PMC: 8826532. DOI: 10.3389/fgene.2021.815448. View

18.

Jiang W, Xia J, Xie S, Zou R, Pan S, Wang Z . Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resist Updat. 2020; 50:100683. DOI: 10.1016/j.drup.2020.100683. View

19.

Bou Antoun N, Chioni A . Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. Int J Mol Sci. 2023; 24(15). PMC: 10418675. DOI: 10.3390/ijms241512222. View

20.

Wang S, Zhang H, Xia L, Lan F . Circular RNA circ_0061140 accelerates hypoxia-induced glycolysis, migration, and invasion in lung adenocarcinoma through the microRNA-653/hexokinase 2 (HK2) axis. Bioengineered. 2022; 13(3):7156-7166. PMC: 9208531. DOI: 10.1080/21655979.2021.2000743. View